Emcure Pharmaceuticals surges on acquiring 20.42% stake in Zuventus Healthcare
Emcure Pharmaceuticals is currently trading at Rs. 1398.35, up by 58.05 points or 4.33% from its previous closing of Rs. 1340.30 on the BSE.
The scrip opened at Rs. 1342.05 and has touched a high and low of Rs. 1407.20 and Rs. 1342.05 respectively. So far 4518 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1530.00 on 15-Oct-2024 and a 52 week low of Rs. 890.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1414.00 and Rs. 1260.10 respectively. The current market cap of the company is Rs. 25961.85 crore.
The promoters holding in the company stood at 77.91%, while Institutions and Non-Institutions held 5.70% and 16.39% respectively.
Emcure Pharmaceuticals has acquired remaining 40,95,180 equity shares constituting 20.42% of Rs 10 each held by individual shareholders in Zuventus Healthcare (Zuventus). With this, Zuventus become a wholly owned subsidiary of the company. Zuventus is involved in the business of dealing in all types, descriptions, specifications, strengths and application of pharmaceutical medicaments in healthcare.
The existing equity shareholding of the company in Zuventus was 79.58%. Post-acquisition, the shareholding of the company in Zuventus is 100%.
Earlier, the board of directors of the company at its meeting held on June 21, 2025, had inter-alia approved the same.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
